NCT05186012 2024-01-23APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaAscentage Pharma Group Inc.Phase 1/2 Unknown51 enrolled